Home

AISLING CAPITAL III LP

CIK 1444717 · last filed 2015-12-15

AISLING CAPITAL III LP is a corporate insider who has filed 9 SEC Form 4 insider transactions across 6 companies since 2011. The most recent filing shows the insider bought $33.0K of LOXO on Dec 15, 2015. Across all open-market trades the lifetime net is +$179.6M, making them a net buyer over the disclosed history. The firm reports its address in New York, NY. 34 SEC filings were submitted jointly with Aisling Capital Partners III LLC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

6

Total Filings

9

Lifetime Open-Market Net

$179.60M

Filer Profile

Reported Address
888 Seventh Avenue, 30th Fl
New York, NY 10106
Phone
(212) 651-6380
State of Incorporation
DE
Related Filers
Aisling Capital Partners III LLC — 34 joint filings, latest 2018-07-12
Aisling Capital Partners III LP — 34 joint filings, latest 2018-07-12
STEVE ELMS — 34 joint filings, latest 2018-07-12
Dennis J Purcell — 34 joint filings, latest 2018-07-12
ANDREW N SCHIFF — 34 joint filings, latest 2018-07-12
Zeltiq Aesthetics Inc — 8 joint filings, latest 2015-11-20
DOV A MD GOLDSTEIN — 2 joint filings, latest 2014-08-06
Sorrento Therapeutics, Inc. — 2 joint filings, latest 2016-02-05
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Loxo Oncology, Inc. (LOXO) Delisted 10%+ Owner 3,796,362 — — $33.0K 1 2015-12-15
T2 Biosystems, Inc. (TTOO) Delisted 10%+ Owner 566 $0.00 $1 $18.00M 1 2015-12-09
Aravive, Inc. (VSAR) Delisted 10%+ Owner 356,595 — — $22.57M 2 2015-01-29
AGILE THERAPEUTICS INC (AGRX) Delisted Director 1,492 $1.51 $2.3K $28.50M 1 2015-01-27
Durata Therapeutics, Inc. (DRTX) Delisted 10%+ Owner 3,030,175 — — $50.50M 2 2014-03-21
Zeltiq Aesthetics Inc (ZLTQ) Delisted 10%+ Owner 2,602,439 — — $60.00M 2 2014-01-27

Recent Filings

9 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2015-12-15 Loxo Oncology, Inc. (LOXO) Delisted Buy (P) +1,200 $33.0K EDGAR
2015-12-09 T2 Biosystems, Inc. (TTOO) Delisted Buy (P) +1,846,152 $18.00M EDGAR
2015-01-29 Aravive, Inc. (VSAR) Delisted Buy (P) +870,000 $15.01M EDGAR
2015-01-27 AGILE THERAPEUTICS INC (AGRX) Delisted Buy (P) +4,871,796 $28.50M EDGAR
2014-03-27 Aravive, Inc. (VSAR) Delisted Mixed +11,967,408 $7.56M EDGAR
2014-03-21 Durata Therapeutics, Inc. (DRTX) Delisted Sell (S) −603,894 -$9.50M EDGAR
2014-01-27 Zeltiq Aesthetics Inc (ZLTQ) Delisted Other (J) −5,944,638 $0 EDGAR
2012-07-25 Durata Therapeutics, Inc. (DRTX) Delisted Mixed +18,784,944 $60.00M EDGAR
2011-10-25 Zeltiq Aesthetics Inc (ZLTQ) Delisted Buy (P) +4,615,386 $60.00M EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.